Matt Nathan Gwilliam1, David John Collins1, Martin O. Leach1, Helen Young2, Matthew R. Orton1
1CRUK and EPSRC Imaging Centre, Institute of Cancer Research, Sutton, London, United Kingdom; 2Astrazeneca, Macclesfield, Cheshire, United Kingdom
DCE-MRI is widely used in clinical trials of antiangiogenic and vascular disrupting agents in the assessment of treatment response. Fitting pharmacokinetic models gives well defined measures of vascular function, but difficulties in obtaining a patient-specific AIF can cause additional errors on PK metrics. This abstract demonstrates that a model-free PCA approach is as sensitive to DCE-MRI treatment changes as model-based PK measures in a group of patients receiving a VEGF inhibitor.